|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM372234291 |
| 003 |
DE-627 |
| 005 |
20240718232925.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240512s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202400196
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1474.xml
|
| 035 |
|
|
|a (DE-627)NLM372234291
|
| 035 |
|
|
|a (NLM)38734875
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ding, Junying
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Activating Iterative Revolutions of the Cancer-Immunity Cycle in Hypoxic Tumors with a Smart Nano-Regulator
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 18.07.2024
|
| 500 |
|
|
|a Date Revised 18.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a The activation of sequential events in the cancer-immunity cycle (CIC) is crucial for achieving effective antitumor immunity. However, formidable challenges, such as innate and adaptive immune resistance, along with the off-target adverse effects of nonselective immunomodulators, persist. In this study, a tumor-selective nano-regulator named PNBJQ has been presented, focusing on targeting two nonredundant immune nodes: inducing immunogenic cancer cell death and abrogating immune resistance to fully activate endogenous tumor immunity. PNBJQ is obtained by encapsulating the immunomodulating agent JQ1 within a self-assembling system formed by linking a Type-I photosensitizer to polyethylene glycol through a hypoxia-sensitive azo bond. Benefiting from the Type-I photosensitive mechanism, PNBJQ triggers the immunogenic cell death of hypoxic tumors under near-infrared (NIR) light irradiation. This process resolves innate immune resistance by stimulating sufficient cytotoxic T-lymphocytes. Simultaneously, PNBJQ smartly responds to the hypoxic tumor microenvironment for precise drug delivery, adeptly addressing adaptive immune resistance by using JQ1 to downregulate programmed death ligand 1 (PD-L1) and sustaining the response of cytotoxic T lymphocytes. The activatable synergic photoimmunotherapy promotes an immune-promoting tumor microenvironment by activating an iterative revolution of the CIC, which remarkably eradicates established hypoxic tumors and suppresses distal lesions under low light dose irradiation
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a activatable nano‐regulator
|
| 650 |
|
4 |
|a cancer immunity cycle
|
| 650 |
|
4 |
|a hypoxic tumor therapy
|
| 650 |
|
4 |
|a immune resistance
|
| 650 |
|
7 |
|a Photosensitizing Agents
|2 NLM
|
| 650 |
|
7 |
|a Triazoles
|2 NLM
|
| 650 |
|
7 |
|a (+)-JQ1 compound
|2 NLM
|
| 650 |
|
7 |
|a Azepines
|2 NLM
|
| 650 |
|
7 |
|a Polyethylene Glycols
|2 NLM
|
| 650 |
|
7 |
|a 3WJQ0SDW1A
|2 NLM
|
| 650 |
|
7 |
|a B7-H1 Antigen
|2 NLM
|
| 700 |
1 |
|
|a Lu, Yang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhao, Xueze
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Long, Saran
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Du, Jianjun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Wen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fan, Jiangli
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Peng, Xiaojun
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 29 vom: 09. Juli, Seite e2400196
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:29
|g day:09
|g month:07
|g pages:e2400196
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202400196
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 29
|b 09
|c 07
|h e2400196
|